Skandinaviska Enskilda Banken AB publ Grows Stock Position in Humana Inc. (NYSE:HUM)

Key Points

• Skandinaviska Enskilda Banken AB increased its holdings in Humana Inc. by 7.0%, owning 25,787 shares valued at approximately $6.8 million as of the end of the last quarter.
• Humana's quarterly earnings surpassed expectations, with an EPS of $11.58, exceeding the consensus estimate of $10.07, alongside a revenue of $32.11 billion.
• Wall Street analysts maintain a consensus "Hold" rating for Humana, with a target price averaging around $282.43.

Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 7.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,787 shares of the insurance provider's stock after buying an additional 1,690 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Humana were worth $6,823,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the fourth quarter valued at approximately $202,000. American Century Companies Inc. boosted its holdings in Humana by 8.8% during the 4th quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider's stock worth $3,211,000 after acquiring an additional 1,027 shares during the last quarter. UniSuper Management Pty Ltd grew its stake in shares of Humana by 32.8% in the 4th quarter. UniSuper Management Pty Ltd now owns 11,227 shares of the insurance provider's stock worth $2,848,000 after acquiring an additional 2,770 shares in the last quarter. NEOS Investment Management LLC lifted its position in shares of Humana by 27.9% during the fourth quarter. NEOS Investment Management LLC now owns 5,697 shares of the insurance provider's stock valued at $1,445,000 after purchasing an additional 1,241 shares in the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Humana in the 4th quarter worth approximately $2,960,000. 92.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Robert W. Baird dropped their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Bank of America reduced their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a report on Sunday, July 20th. Finally, Barclays set a $275.00 price target on shares of Humana in a report on Thursday. Sixteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $282.00.

Humana Stock Performance

NYSE HUM traded down $8.03 during trading hours on Thursday, hitting $253.45. 1,140,339 shares of the company's stock traded hands, compared to its average volume of 1,736,470. The firm has a market capitalization of $30.59 billion, a P/E ratio of 17.94, a P/E/G ratio of 1.59 and a beta of 0.44. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The business's fifty day moving average price is $234.17 and its two-hundred day moving average price is $255.74. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.42% and a return on equity of 14.47%. The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter in the previous year, the firm earned $6.96 earnings per share. Humana's revenue was up 9.6% on a year-over-year basis. Equities research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.